A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System | MicrobiomeTrials← Back to trialsNCT07194265
A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-10-21Est. Completion: 2027-12
Enrollment target: 1,650 participants Locations- Kaiser Permanente San Francisco, San Francisco, California, United States
- Montefiore Medical Center, The Bronx, New York, United States
- The Stern Cardiovascular Foundation, Germantown, Tennessee, United States
- Rigshospitalet, Copenhagen, Capital Region of Denmark, Denmark
- Aarhus University Hospital, Aarhus, Denmark
Other microbiome trials you might be interested in
Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutati…
Xi'an, ChinaEst. completion Dec 31, 2030
Aortic Valve Stenosis
Aortic valve stenosis is the most common valve disease leading to surgical or percutaneous intervention in Europe and No…
Brest, FranceEst. completion Nov 23, 2027